BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCRX BioCryst制药

已收盘 11-22 16:00:00 EST

7.60

+0.11

+1.47%

盘后7.60

+0.000.00%

19:18 EST

最高7.66	最低7.42	成交量197.74万
今开7.46	昨收7.49	日振幅3.20%
总市值15.74亿	流通市值14.70亿	总股本2.07亿
成交额1,498万	换手率1.02%	流通股本1.93亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"BioCryst制药","latestPrice":7.6,"timestamp":1732309200000,"preClose":7.49,"halted":0,"volume":1977407,"hourTrading":{"tag":"盘后","latestPrice":7.6,"preClose":7.6,"latestTime":"19:18 EST","volume":96264,"amount":731628.41,"timestamp":1732321111115},"delay":0,"floatShares":193357965,"shares":207132571,"eps":-0.603319,"marketStatus":"已收盘","marketStatusCode":5,"change":0.11,"latestTime":"11-22 16:00:00 EST","open":7.46,"high":7.66,"low":7.42,"amount":14983637.417719,"amplitude":0.032043,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.603319,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":0,"listingDate":762670800000,"adjPreClose":7.49,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":7.46,"preClose":7.49,"latestTime":"09:29 EST","volume":887,"amount":6617.9001701,"timestamp":1732285799999},"postHourTrading":{"tag":"盘后","latestPrice":7.6,"preClose":7.6,"latestTime":"19:18 EST","volume":96264,"amount":731628.41,"timestamp":1732321111115},"volumeRatio":1.01646,"impliedVol":0.3299,"impliedVolPercentile":0.0317},"requestUrl":"/m/hq/s/BCRX","defaultTab":"news","newsList":[{"id":"2483052912","title":"BioCryst制药盘中异动 快速下挫5.00%报7.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483052912","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483052912?lang=zh_cn&edition=full","pubTime":"2024-11-13 04:56","pubTimestamp":1731444983,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日04时56分，BioCryst制药股票出现波动，股价急速跳水5.00%。截至发稿，该股报7.78美元/股，成交量101.718万股，换手率0.49%，振幅5.56%。BioCryst制药股票所在的生物技术行业中，整体跌幅为1.05%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113045624971a61df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113045624971a61df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2482176849","title":"BioCryst制药盘中异动 临近收盘急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482176849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482176849?lang=zh_cn&edition=full","pubTime":"2024-11-12 04:34","pubTimestamp":1731357256,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日04时34分，BioCryst制药股票出现波动，股价快速上涨5.08%。截至发稿，该股报8.18美元/股，成交量95.6529万股，换手率0.46%，振幅3.79%。BioCryst制药股票所在的生物技术行业中，整体跌幅为0.91%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111204341698e41e0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111204341698e41e0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2482948427","title":"BioCryst制药2024财年第三财季实现净利润-14.03百万美元，同比增加61.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482948427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482948427?lang=zh_cn&edition=full","pubTime":"2024-11-10 00:02","pubTimestamp":1731168128,"startTime":"0","endTime":"0","summary":"11月10日，BioCryst制药公布财报，公告显示公司2024财年第三财季净利润为-14.03百万美元，同比增加61.19%；其中营业收入为1.17亿美元，同比增加34.89%，每股基本收益为-0.07美元。从资产负债表来看，BioCryst制药总负债9.60亿美元，其中短期债务35.89百万美元，资产负债比为0.52，流动比率为2.78。机构评级：截至2024年11月10日，当前有10家机构对BioCryst制药目标价做出预测，其中目标均价为15.10美元，其中最低目标价为8.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000237a227863e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000237a227863e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX"],"gpt_icon":0},{"id":"2481986472","title":"BioCryst制药盘中异动 股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481986472","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481986472?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:49","pubTimestamp":1730904587,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时49分，BioCryst制药股票出现波动，股价快速上涨5.17%。截至发稿，该股报7.42美元/股，成交量39.4325万股，换手率0.19%，振幅4.25%。BioCryst制药股票所在的生物技术行业中，整体跌幅为0.97%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106224948aba6bb76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106224948aba6bb76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2481508022","title":"美国研究综述-塞拉尼斯公司、Disc Medicine、Editas Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2481508022","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481508022?lang=zh_cn&edition=full","pubTime":"2024-11-05 20:32","pubTimestamp":1730809940,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对塞拉尼斯公司、Disc Medicine 和 Editas Medicine 等几家美国上市公司的评级和目标价。* Disc Medicine Inc   ：雷蒙德-詹姆斯将其评级从 \"跑赢大盘 \"上调至 \"强力买入\"。* Editas Medicine Inc   ：雷蒙德-詹姆斯将其评级从 \"跑赢大市 \"下调至 \"跑赢大市\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRON","BK4109","ARES","CRUS","CW","EGHT","CNP","BOWL","BCRX","CRGY","LU2087625088.SGD","CE","CHH","BK4178","DG","AIG","AFL","LU1699723380.USD","ATUS","CEG","BFAM","ABG","CAMP","LNG","BKNG","ADVM","CNC","AMG","LU2065169927.USD","CBT","ARHS","CAR","CRBG","CDNA","CHE","IE00BVYPNW00.USD","IE00BKVL7J92.USD","HIMS","AN","BMRN","CBLL","CI","CSTL","BWIN","CMS","LU0289739699.SGD","LU1496350502.SGD","BK4208","AWI","CC"],"gpt_icon":1},{"id":"1172966698","title":"异动解读 | BioCryst制药盘中大跌 业绩疲软或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1172966698","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172966698?lang=zh_cn&edition=full","pubTime":"2024-11-04 23:30","pubTimestamp":1730734232,"startTime":"0","endTime":"0","summary":"BioCryst制药今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。不过也有分析人士认为,当前股价剧烈波动可能还与大资金的资金流出有关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCRX"],"gpt_icon":0},{"id":"2480587958","title":"BioCryst Pharmaceuticals Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2480587958","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480587958?lang=zh_cn&edition=full","pubTime":"2024-11-04 23:26","pubTimestamp":1730734012,"startTime":"0","endTime":"0","summary":"   * BioCryst Pharmaceuticals Inc   报告了截至9月30日的季度调整后每股亏损7美分，高于去年同期的每股-19美分。10位分析师对该季度的平均预期是每股亏损6美分。华尔街预期为每股-9美分至-3美分。* BioCryst Pharmaceuticals Inc公布的本季度每股收益为亏损7美分。* 该公司的季度亏损额为 1403 万美元。* BioCryst Pharmaceuticals Inc 的股价本季度上涨了 10.9%，今年迄今为止上涨了 40.7%。华尔街对 BioCryst Pharmaceuticals Inc 的 12 个月目标价中位数为 11.00 美元。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCryst Pharmaceuticals Inc 报告截至 9 月 30 日的季度业绩 - 收益摘要","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2480848045","title":"BioCryst制药盘中异动 股价大跌11.63%报7.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480848045","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480848045?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:31","pubTimestamp":1730730702,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时31分，BioCryst制药股票出现波动，股价快速下挫11.63%。截至发稿，该股报7.45美元/股，成交量22.2104万股，换手率0.11%，振幅6.64%。BioCryst制药股票所在的生物技术行业中，整体涨幅为0.14%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422314395bdc9b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422314395bdc9b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2480526148","title":"BioCryst制药盘中异动 股价大涨5.18%报8.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480526148","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480526148?lang=zh_cn&edition=full","pubTime":"2024-11-02 03:58","pubTimestamp":1730491124,"startTime":"0","endTime":"0","summary":"北京时间2024年11月02日03时58分，BioCryst制药股票出现异动，股价急速拉升5.18%。截至发稿，该股报8.43美元/股，成交量222.894万股，换手率1.08%，振幅5.24%。BioCryst制药股票所在的生物技术行业中，整体涨幅为0.48%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102035844ab948a66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102035844ab948a66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX","BK4139","BK4547"],"gpt_icon":0},{"id":"2477630596","title":"BUZZ-基因治疗研究中期数据不尽如人意，Intellia业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2477630596","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477630596?lang=zh_cn&edition=full","pubTime":"2024-10-24 22:31","pubTimestamp":1729780273,"startTime":"0","endTime":"0","summary":"** HAE的特征是皮肤、胃肠道、上呼吸道系统、面部和喉咙不可预测地频繁出现严重肿胀。** 我们预计，考虑到体内基因编辑的潜在风险和该适应症的竞争格局，投资者会认为 HAE 发作减少 75-80% 的结果并不令人印象深刻。** 美国目前批准的HAE治疗药物包括武田药品  和BioCryst Pharmaceuticals  生产的药物。** 包括盘中走势在内，Intellia 的股价今年以来下跌了约 46","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU0106261612.USD","BK4535","BK4139","LU0205193047.USD","BCRX","IE00BLDYK493.USD","NTLA","LU0012050646.USD","HAE","BK4547","LU1861558580.USD","LU1169590202.USD","BK4556","LU0205194284.USD","BK4588","IE00B64QTZ34.USD","BK4198","LU1861559042.SGD","BK4585"],"gpt_icon":0},{"id":"2477635433","title":"BioCryst制药盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477635433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477635433?lang=zh_cn&edition=full","pubTime":"2024-10-22 23:16","pubTimestamp":1729610169,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日23时16分，BioCryst制药股票出现异动，股价急速拉升5.05%。截至发稿，该股报7.90美元/股，成交量52.3233万股，换手率0.25%，振幅6.06%。BioCryst制药股票所在的生物技术行业中，整体跌幅为0.40%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022231610971a1a2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022231610971a1a2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2469223371","title":"BioCryst制药盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469223371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469223371?lang=zh_cn&edition=full","pubTime":"2024-09-24 03:38","pubTimestamp":1727120290,"startTime":"0","endTime":"0","summary":"北京时间2024年09月24日03时38分，BioCryst制药股票出现波动，股价急速跳水5.18%。截至发稿，该股报7.69美元/股，成交量115.25万股，换手率0.56%，振幅5.49%。BioCryst制药股票所在的生物技术行业中，整体跌幅为2.67%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092403381098e387e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092403381098e387e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2466410781","title":"BUZZ-澳大利亚 Island 制药公司收购抗病毒分子公司，业绩大幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2466410781","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466410781?lang=zh_cn&edition=full","pubTime":"2024-09-11 09:19","pubTimestamp":1726017549,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    9月11日 - ** Island Pharmaceuticals   股价上涨9.1%至0.084澳元，创6月18日以来新高。** 制药公司称， (link)，它与 BioCryst   签署了一份具有约束力的意向书，可能收购抗病毒分子加来地韦，费用为 5 万美元。** 如果涨势保持，股价将创下自 8 月 7 日以来的最佳表现 ** 截至格林尼治标准时间 0110，ILA 累计下跌 1.7","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ILA.AU","BK4547","BK7096","BCRX"],"gpt_icon":0},{"id":"2458679682","title":"BioCryst制药2024财年第二财季实现净利润-12.67百万美元，同比增加83.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458679682","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458679682?lang=zh_cn&edition=full","pubTime":"2024-08-11 00:20","pubTimestamp":1723306829,"startTime":"0","endTime":"0","summary":"8月11日，BioCryst制药公布财报，公告显示公司2024财年第二财季净利润为-12.67百万美元，同比增加83.18%；其中营业收入为1.09亿美元，同比增加32.14%，每股基本收益为-0.06美元。从资产负债表来看，BioCryst制药总负债9.48亿美元，其中短期债务31.68百万美元，资产负债比为0.50，流动比率为2.82。机构评级：截至2024年8月11日，当前有11家机构对BioCryst制药目标价做出预测，其中目标均价为14.45美元，其中最低目标价为7.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240811002037958e75bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240811002037958e75bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCRX"],"gpt_icon":0},{"id":"2458429673","title":"BioCryst制药盘中异动 急速上涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458429673","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458429673?lang=zh_cn&edition=full","pubTime":"2024-08-09 00:49","pubTimestamp":1723135752,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日00时49分，BioCryst制药股票出现异动，股价大幅上涨5.11%。截至发稿，该股报7.82美元/股，成交量70.586万股，换手率0.34%，振幅5.78%。BioCryst制药股票所在的生物技术行业中，整体涨幅为2.48%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080900491396825398&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080900491396825398&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2457294608","title":"BioCryst制药盘中异动 大幅下挫5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457294608","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457294608?lang=zh_cn&edition=full","pubTime":"2024-08-08 00:01","pubTimestamp":1723046481,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日00时01分，BioCryst制药股票出现波动，股价快速下跌5.21%。截至发稿，该股报7.46美元/股，成交量136.63万股，换手率0.66%，振幅6.61%。BioCryst制药股票所在的生物技术行业中，整体跌幅为1.54%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。Biocryst的研究基于多种科学学科，如生物学、计算机建模和药物化学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808000121aefdbd6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808000121aefdbd6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BCRX","BK4547"],"gpt_icon":0},{"id":"2457139006","title":"BioCryst制药盘中异动 急速上涨5.06%报7.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457139006","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457139006?lang=zh_cn&edition=full","pubTime":"2024-08-07 03:59","pubTimestamp":1722974371,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日03时59分，BioCryst制药股票出现波动，股价大幅上涨5.06%。截至发稿，该股报7.89美元/股，成交量316.529万股，换手率1.53%，振幅6.86%。BioCryst制药股票所在的生物技术行业中，整体涨幅为1.25%。BioCryst制药公司简介：BioCryst Pharmaceuticals Inc 是一家生物技术公司，主要从事新型小分子药物的研究和开发，以阻断感染和炎症疾病的关键酶。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807035931941feb15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807035931941feb15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BCRX","BK4547"],"gpt_icon":0},{"id":"2457044026","title":"美国研究综述-Actinium Pharmaceuticals、Albemarle、ArcBest","url":"https://stock-news.laohu8.com/highlight/detail?id=2457044026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457044026?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:56","pubTimestamp":1722949016,"startTime":"0","endTime":"0","summary":"    路透8月6日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Actinium Pharmaceuticals、Albemarle 和 ArcBest。要点   * Actinium Pharmaceuticals Inc   ：JonesTrading将其交易价格从26美元下调至9美元 * Albemarle   ：Baird将其评级下调至中性，目标价从102美元下调至85美元 * ArcBest Corp   ：Stephens 将目标价从 145 美元下调至 130 美元 * Crispr Therapeutics AG   ：Leerink Partners将目标价从80美元下调至68美元 * Warrior Met Coal Inc   ：杰富瑞将目标价从85美元下调至78美元 以下是路透周二报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNT","ATIP","BMRN","CWT","ADUS","BK4129","BK4519","ETNB","BCRX","AN","ALL","AMWL","AXSM","BK4231","CABO","ALHC","LU1323610961.USD","CBT","AHR","AQMS","IE00B1XK9C88.USD","LU","LU1978683503.SGD","BN","AEE","AMRC","LU0354030511.USD","BKH","ANAB","ASPN","BK","AKYA","AEP","ARCH","AIG","ALB","AES","APO","ALX","CTRE","CDNS","LU0648001328.SGD","IE00BKDWB100.SGD","BIIB","CG","ARCB"],"gpt_icon":1},{"id":"2457041731","title":"加拿大皇家银行：重申BioCryst Pharma(BCRX.US)评级，由优于大市调整至优于大市评级, 目标价由10.00美元调整至10.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457041731","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457041731?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:34","pubTimestamp":1722947648,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2457084927","title":"成分股Marinus Pharma收跌15.38%，Fulcrum Therapeutics跌11.41%，bluebird bio跌10.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457084927","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457084927?lang=zh_cn&edition=full","pubTime":"2024-08-06 06:17","pubTimestamp":1722896264,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK4503","BK4209","DASH","BK4549","BK4505","BK4585","BK4551","BK4535","BK4588","BK4007","BK4547","FULC","NDX","BCRX","BK4139","BK4548","LENZ","BK4122","BK4536","LXRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":-0.0579},{"period":"3month","weight":-0.0753},{"period":"6month","weight":0.2219},{"period":"1year","weight":0.3948},{"period":"ytd","weight":0.2504}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioCryst Pharmaceuticals, Inc.是一家生物技术公司，致力于设计、优化和开发新的药物，新的药物主要是阻止疾病的发病机制的关键酶。该公司是一家始建于1986年的特拉华州公司，该公司专注于治疗领域有未满足的医疗需求，并将其能力与专长联系在一起。公司的利益区域和候选药物的相关开发是由科学发现和潜在的优势，其经验丰富的药物研发组标识，以及这些发现内潜在的商业机会来决定的。该公司通过名为结构导向药物设计过程整合生物学，晶体学，药物化学和计算机模拟等学科，发现和开发小分子药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":0.030527},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014169},{"month":3,"riseRate":0.366667,"avgChangeRate":0.019768},{"month":4,"riseRate":0.548387,"avgChangeRate":0.044665},{"month":5,"riseRate":0.548387,"avgChangeRate":0.05805},{"month":6,"riseRate":0.612903,"avgChangeRate":0.033442},{"month":7,"riseRate":0.580645,"avgChangeRate":0.119811},{"month":8,"riseRate":0.580645,"avgChangeRate":0.102213},{"month":9,"riseRate":0.354839,"avgChangeRate":-0.048294},{"month":10,"riseRate":0.516129,"avgChangeRate":-0.047322},{"month":11,"riseRate":0.483871,"avgChangeRate":0.039361},{"month":12,"riseRate":0.466667,"avgChangeRate":0.002044}],"exchange":"NASDAQ","name":"BioCryst制药","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioCryst制药(BCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioCryst制药,BCRX,BioCryst制药股票,BioCryst制药股票老虎,BioCryst制药股票老虎国际,BioCryst制药行情,BioCryst制药股票行情,BioCryst制药股价,BioCryst制药股市,BioCryst制药股票价格,BioCryst制药股票交易,BioCryst制药股票购买,BioCryst制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCryst制药(BCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioCryst制药(BCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}